Создавая историю на страницах книги диффузной В-крупноклеточной лимфомы. Объединенный VI Конгресс гематологов России и III Конгресс трансфузиологов. Обзор симпозиума 21 апреля 2022 г., Москва

Создавая историю на страницах книги диффузной В-крупноклеточной лимфомы. Современная Онкология. 2022;24(2):150–157. DOI: 10.26442/18151434.2022.2.201711

________________________________________________

Creating a story on the pages of a book about diffuse B-large cell lymphoma. Journal of Modern Oncology. 2022;24(2):150–157. DOI: 10.26442/18151434.2022.2.201711

Читать PDF

Аннотация

В рамках Объединенного VI Конгресса гематологов России и III Конгресса трансфузиологов России 21 апреля состоялся симпозиум, посвященный диффузной В-крупноклеточной лимфоме (ДВКЛ). Ведущие российские эксперты обсудили современные тенденции в диагностике, причины неудач и успехов терапии этого гетерогенного заболевания, изменения, которые ожидаются в самое ближайшее время. Во время симпозиума были представлены подробные данные о новой опции терапии ДВКЛ – иммуноконъюгате полатузумабе ведотине. Симпозиум проведен при поддержке компании «Рош».

Ключевые слова: диффузная В-крупноклеточная лимфома, химиотерапия, иммунотерапия, таргетная терапия, иммуноконъюгаты, полатузумаб ведотин, исследование POLARIX, исследование GO29365

________________________________________________

Within the framework of VI All-Union Congress of Hematologists of Russia and III Congress of Transfusiologists of Russia, the symposium concerning diffuse large B cell lymphoma (DLBCL) was held on April 21. Leading Russian experts discussed current trends in diagnosis, the causes of the failures and successes of the treatment of this heterogeneous disease, the changes that are expected in the very near future. During the symposium, the detailed data concerning the new option for DLBCL therapy – polatuzumab vedotin (immunoconjugate) were also presented. The symposium was supported by Roche.

Keywords: diffuse large B cell lymphoma, chemotherapy, immunotherapy, targeted therapy, immunoconjugates, polatuzumab vedotin, the POLARIX trial, the GO29365 trial

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Cancer death rates are falling; five-year survival rates are rising. Available: https://ourworldindata.org/cancer-death-rates-are-falling-five-year-survival-rates-are-rising/ Accessed: 18.04.2022.
2. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-407. DOI:10.1056/NEJMoa1801445
3. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-90. DOI:10.1038/s41591-018-0016-8
4. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551-68.e14. DOI:10.1016/j.ccell.2020.03.015
5. Feugier P, Hoof AV, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-26. DOI:10.1200/JCO.2005.09.131
6. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. DOI:10.1182/blood-2017-03-769620
7. Клинические рекомендации по лечению агрессивных нефолликулярных лимфом. Проект 2021–2022. Режим доступа: https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Ссылка активна на 18.04.2022 [Klinicheskie rekomendatsii po lecheniiu agressivnykh nefollikuliarnykh lim-fom. Proekt 2021–2022. Available:https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Accessed: 18.04.2022 (in Russian)].
8. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-15. DOI:10.1016/S1470-2045(15)70128-2
9. Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721-9. DOI:10.1182/blood-2009-02-205500
10. Polson A, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Invest Drug. 2011;20:75-85. DOI:10.1517/13543784.2011.539557
11. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458‑65. DOI:10.1182/blood-2003-01-0039
12. Beck A, Lambert J, Sun M, et al. Fourth World Antibody-Drug Conjugate Summit: February 29 – March 1, 2012, Frankfurt, Germany. MAbs. 2012;4(6):637‑47. DOI:10.4161/mabs.21697
13. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-65. DOI:10.1200/JCO.19.00172
14. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-43. DOI:10.1182/bloodadvances.2021005794
15. Zhang M, Xu P, Wang L, et al. Genetic Subtype Guided Rituximab-Based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-Cell Lymphoma: First Report of a Randomized Phase 2 Study. Hematol Oncol. 2021;39(Suppl. 2). DOI:10.1002/hon.26_2879
16. Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735-42. DOI:10.1038/s41591-022-01731-4
17. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-63. DOI:10.1056/NEJMoa2115304

________________________________________________

1. Cancer death rates are falling; five-year survival rates are rising. Available: https://ourworldindata.org/cancer-death-rates-are-falling-five-year-survival-rates-are-rising/ Accessed: 18.04.2022.
2. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-407. DOI:10.1056/NEJMoa1801445
3. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-90. DOI:10.1038/s41591-018-0016-8
4. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551-68.e14. DOI:10.1016/j.ccell.2020.03.015
5. Feugier P, Hoof AV, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-26. DOI:10.1200/JCO.2005.09.131
6. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. DOI:10.1182/blood-2017-03-769620
7. Klinicheskie rekomendatsii po lecheniiu agressivnykh nefollikuliarnykh lim-fom. Proekt 2021–2022. Available:https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Accessed: 18.04.2022 (in Russian).
8. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-15. DOI:10.1016/S1470-2045(15)70128-2
9. Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721-9. DOI:10.1182/blood-2009-02-205500
10. Polson A, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Invest Drug. 2011;20:75-85. DOI:10.1517/13543784.2011.539557
11. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458‑65. DOI:10.1182/blood-2003-01-0039
12. Beck A, Lambert J, Sun M, et al. Fourth World Antibody-Drug Conjugate Summit: February 29 – March 1, 2012, Frankfurt, Germany. MAbs. 2012;4(6):637‑47. DOI:10.4161/mabs.21697
13. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-65. DOI:10.1200/JCO.19.00172
14. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-43. DOI:10.1182/bloodadvances.2021005794
15. Zhang M, Xu P, Wang L, et al. Genetic Subtype Guided Rituximab-Based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-Cell Lymphoma: First Report of a Randomized Phase 2 Study. Hematol Oncol. 2021;39(Suppl. 2). DOI:10.1002/hon.26_2879
16. Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735-42. DOI:10.1038/s41591-022-01731-4
17. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-63. DOI:10.1056/NEJMoa2115304

Авторы

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.